cervical cancer
Conditions
Interventions
Anlotinib combined with concurrent chemoradiotherapy:Anlotinib combined with concurrent chemoradiotherapy
Sponsors
Yili Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate and sign informed consent in writing; 2. Aged 18-75 years; 3. Histologically confirmed cervical cancer; 4. Clinical stage IB3, IIA2-IV; 5. Primary treatment (have not received anti-tumor therapy such as radiotherapy, chemotherapy, molecular targeting, and immunity before); 6. The primary tumor is measurable; 7. No distant organ metastases; 8. Karnofsky score > 70; 9. Survival expected >= 3 months; 10. Women of childbearing potential should ensure contraception during study entry; 11. Hemoglobin >= 100 g/L, WBC >= 4x10^9/L, platelets >= 100x10^9/L; 12. Liver function: ALT, AST 50%, the percentage of DLCO (diffusing function of lung) measured value and predicted value > 80%; 15. The patient has good compliance with the treatment and follow-up received.
Exclusion criteria
Exclusion criteria: 1. The primary tumor or lymph nodes have been surgically treated (except biopsy); 2. Diagnosis of other malignancies (other than cured in situ cervical carcinoma/basal cell carcinoma of the skin/bladder epithelial tumor) 5 years prior to the start of the study; 3. Subjects who have received other drug trials within the past 1 month; 4. Pregnant or breastfeeding women and women who refuse contraception during the treatment observation period; 5. Those with a history of severe allergies or idiosyncratic constitutions; 6. Those with a history of severe lung or heart disease; 7. People who are drug or alcohol addicts; 8. Persons with personality or mental disorders, no capacity for civil conduct or limited capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety;radiotherapy response;2- and 3-year local control rates;2- and 3-year DFSR (Disease-Free Survival rate);2- and 3-year OSR (overall survival rate);BIOMARKER; | — |
Countries
China
Contacts
Public ContactHongfei Liu
Yili Friendship Hospital
Outcome results
None listed